IDx-DR, an autonomous artificial intelligence-based diagnostic system for the detection of diabetic retinopathy in primary care offices, outperformed all prespecified superiority endpoints of sensitivity, specificity and imageability rates, according to the results of a clinical trial.
After the results were released, the FDA cleared the system in April for use by health care providers to detect more than mild diabetic retinopathy and diabetic macular edema, Michael D. Abramoff, MD, PhD, told Ocular Surgery News. Abramoff is founder and CEO of IDx, the company that developed the system.
“This
Uncategorized